← All trials
NCT05470465
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jul 22, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 25
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Food and Drug AdministrationLead sponsor
- Leiden UniversityCollaborator
- Spaulding Clinical Research Inc.Collaborator
- Spaulding Clinical Research Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.